GlaxoSmithKline R&D, Medicines Research Centre , Gunnels Wood Road , SG1 2NY Stevenage , U.K.
J Med Chem. 2018 Dec 27;61(24):11061-11073. doi: 10.1021/acs.jmedchem.8b01556. Epub 2018 Dec 21.
A deconstruction of previously reported phosphoinositide 3-kinase δ (PI3Kδ) inhibitors and subsequent regrowth led to the identification of a privileged fragment for PI3Kδ, which was exploited to deliver a potent, efficient, and selective lead series with a novel binding mode observed in the PI3Kδ crystal structure.
对先前报道的磷酸肌醇 3-激酶 δ(PI3Kδ)抑制剂进行解构,随后重新生长,从而确定了 PI3Kδ 的一个特权片段,该片段被用于开发一种有效的、选择性的先导化合物系列,在 PI3Kδ 的晶体结构中观察到了一种新的结合模式。